Ricardo Dent

2.6k total citations · 2 hit papers
41 papers, 2.0k citations indexed

About

Ricardo Dent is a scholar working on Surgery, Economics and Econometrics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ricardo Dent has authored 41 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Surgery, 18 papers in Economics and Econometrics and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ricardo Dent's work include Lipoproteins and Cardiovascular Health (36 papers), Pharmaceutical Economics and Policy (13 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Ricardo Dent is often cited by papers focused on Lipoproteins and Cardiovascular Health (36 papers), Pharmaceutical Economics and Policy (13 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Ricardo Dent collaborates with scholars based in United States, Switzerland and Netherlands. Ricardo Dent's co-authors include Scott M. Wasserman, Robert S. Rosenson, Robert C. Scott, Maciej Banach, Peter P. Tóth, Allen Xue, Erik S.G. Stroes, David Sullivan, Gerald F. Watts and Tomáš Štulc and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Ricardo Dent

37 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

2014 421 citations Erik S.G. Stroes, David Colquhoun et al. Journal of the American College of Cardiology profile →
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ricardo Dent United States	20	1.6k	684	343	296	234	41	2.0k
Norman E. Lepor United States	8	1.8k 1.1×	656 1.0×	473 1.4×	460 1.6×	275 1.2×	13	2.4k
Patrick M. Moriarty United States	18	1.3k 0.8×	332 0.5×	349 1.0×	394 1.3×	282 1.2×	40	1.7k
Estella Kanevsky United States	10	1.8k 1.1×	472 0.7×	554 1.6×	659 2.2×	274 1.2×	15	2.1k
Mahfouz El Shahawy United States	6	1.5k 0.9×	599 0.9×	397 1.2×	445 1.5×	198 0.8×	11	1.9k
David Neff United States	17	938 0.6×	299 0.4×	394 1.1×	269 0.9×	233 1.0×	39	1.4k
Traci Turner United States	12	1.8k 1.1×	568 0.8×	487 1.4×	478 1.6×	430 1.8×	39	2.4k
Daniel A. Gipe United States	13	1.7k 1.1×	577 0.8×	573 1.7×	736 2.5×	447 1.9×	24	2.1k
Armando Lira Pineda United States	13	2.3k 1.4×	594 0.9×	731 2.1×	800 2.7×	368 1.6×	21	2.8k
Norman E. Lepor United States	19	1.0k 0.6×	243 0.4×	426 1.2×	580 2.0×	178 0.8×	79	1.9k
Claudia Stefanutti Italy	25	1.7k 1.0×	276 0.4×	689 2.0×	667 2.3×	439 1.9×	98	2.2k

Countries citing papers authored by Ricardo Dent

Since Specialization

Citations

This map shows the geographic impact of Ricardo Dent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricardo Dent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricardo Dent more than expected).

Fields of papers citing papers by Ricardo Dent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricardo Dent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricardo Dent. The network helps show where Ricardo Dent may publish in the future.

Co-authorship network of co-authors of Ricardo Dent

This figure shows the co-authorship network connecting the top 25 collaborators of Ricardo Dent. A scholar is included among the top collaborators of Ricardo Dent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricardo Dent. Ricardo Dent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mefford, Matthew T., Gabriel S. Tajeu, Rikki M. Tanner, et al.. (2018). Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). The American Journal of Cardiology. 122(5). 768–774. 15 indexed citations

Hovingh, G. Kees, Frederick J. Raal, Ricardo Dent, et al.. (2017). Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 11(6). 1448–1457. 48 indexed citations

Rosenson, Robert S., Shravanthi R. Gandra, Jan McKendrick, et al.. (2017). Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. Cardiovascular Drugs and Therapy. 31(2). 187–195. 15 indexed citations

Soran, Handrean, Ricardo Dent, & Paul N. Durrington. (2017). Evidence-based goals in LDL-C reduction. Clinical Research in Cardiology. 106(4). 237–248. 68 indexed citations

Tanner, Rikki M., Monika M. Safford, Keri L. Monda, et al.. (2016). Abstract 15687: Reasons for Statin Discontinuation With and Without a Physician’s Advice: Data From the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circulation. 134. 1 indexed citations

Tóth, Peter P., Olivier Descamps, Jacques Genest, et al.. (2016). A POOLED SAFETY ANALYSIS OF OVER 6000 PATIENTS FROM DOUBLE-BLIND AND OPEN-LABEL EXTENSION STUDIES WITH EVOLOCUMAB. Journal of the American College of Cardiology. 67(13). 1865–1865. 3 indexed citations

McKendrick, J, et al.. (2016). Identification of Statin Intolerance: Results From A Survey of Clinicians in Taiwan. Value in Health. 19(7). A872–A872.

Banach, Maciej, Tomáš Štulc, Ricardo Dent, & Peter P. Tóth. (2016). Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology. 225. 184–196. 146 indexed citations

McKendrick, J, et al.. (2016). Management of Patients with Statin Intolerance in Japan, South Korea and Taiwan: Comparison of Results From A Clinician Survey. Value in Health. 19(7). A872–A872. 1 indexed citations

10.

Blom, Dirk, et al.. (2016). PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vascular Health and Risk Management. 12. 185–185. 19 indexed citations

11.

Cho, Leslie, Michael Rocco, David Colquhoun, et al.. (2016). Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovascular Drugs and Therapy. 30(3). 297–304. 15 indexed citations

12.

Dent, Ricardo, C. Stephen Djedjos, Jason C. Legg, et al.. (2016). Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 5(1). 300–300. 20 indexed citations

13.

Rosenson, Robert S., Terry A. Jacobson, David Preiss, et al.. (2016). Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular Drugs and Therapy. 30(3). 305–313. 23 indexed citations

14.

Hovingh, G. Kees, Shravanthi R. Gandra, Jan McKendrick, et al.. (2015). Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis. 245. 111–117. 45 indexed citations

15.

Tóth, Peter P., Naveed Sattar, Jacques Genest, et al.. (2015). A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145). Journal of the American College of Cardiology. 65(10). A1351–A1351. 8 indexed citations

16.

Cho, Leslie, Michael Rocco, David Colquhoun, et al.. (2014). Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. Clinical Cardiology. 37(3). 131–139. 25 indexed citations

17.

Raal, Frederick J., Robert P. Giugliano, Marc S. Sabatine, et al.. (2014). Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology. 63(13). 1278–1288. 281 indexed citations breakdown →

18.

Bhandari, Mohit, Scott M. Wasserman, Nicole Yurgin, et al.. (2013). Development and preliminary validation of a Function IndeX for Trauma (FIX-IT). Canadian Journal of Surgery. 56(5). E114–E120. 12 indexed citations

19.

Hernandez, Rohini K., Thy P., Cathy W. Critchlow, Ricardo Dent, & Susan S. Jick. (2012). Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthopaedica. 83(6). 653–660. 167 indexed citations

20.

Dent, Ricardo, et al.. (1977). A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in treatment of hypertension.. PubMed. 86(595). 213–5. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact